The global market for cancer drugs will grow twice as fast as that for all other pharmaceuticals as the developing world spends more on health care, a new report says.
China, Brazil, Russia and other emerging countries are becoming bigger customers for pharmaceuticals, as they invest more in treating and diagnosing cancer, a report issued by IMS Health yesterday said.
The healthcare research firm expects pharmaceutical spending in countries such as India, Mexico and Turkey to grow by 12 percent to 13 percent over the next 15 years, compared with single-digit growth for more developed nations.
Cancer drug spending is expected to grow between 12 percent and 15 percent annually through 2012 to US$75 billion to US$80 billion, the report said. The overall drug market is expected to grow at 6.4 percent.
Feeding that demand are the multibillion-dollar research and development budgets of firms like Genentech Inc, Amgen Inc and Novartis AG.
“Oncology is the top of the bill when it comes to new products in development,” said Titus Pattel, a vice president at IMS. “Oncology R&D dwarfs all other research efforts within these organizations.”
Cancer drug sales are expected to reach US$48 billion this year, led by Genentech’s breast cancer drug Herceptin, Novartis’ leukemia drug Gleevec and other blockbusters.
But the market is not immune to a slowdown. Expiring patents on older cancer drugs and efforts to tighten healthcare spending could limit future growth, IMS said.
Some European countries have begun paying drug companies based on how successfully their drugs treat patients. The Italian government, for example, only began reimbursing Johnson & Johnson for the cancer treatment Velcade after the drug demonstrated positive results in patients. IMS said that the adoption of similar policies in the US could slow spending on cancer medications.
Pharmaceutical firms also face a tougher regulatory environment in the US, where the Food and Drug Administration (FDA) has delayed several highly anticipated cancer therapies.
Last year, the agency denied approval of Dendreon’s prostate cancer vaccine Provenge, despite an overwhelmingly positive review by the agency’s outside advisers.
“There’s a tendency from the FDA to be more conservative than they have over the last 10 years,” Pattel said.
An aggressive review environment could dampen the market for between 25 and 30 new anticancer drugs currently in development, the IMS report says. At the same time, some of the biggest blockbuster cancer drugs of the last decade will lose their patent protection, including Sanofi-Aventis’ Taxotere and AstraZeneca PLC’s Arimidex.
Expiring drug patents and an increasingly crowded market for cancer therapies will lower spending in the US and Europe. These markets are expected to account for 65 percent of the global cancer drugs market by 2012, down from 71 percent last year, IMS said.
The company’s forecast comes ahead of the American Society of Clinical Oncology’s annual meeting, which begins on May 30.
Abstracts for company studies were to be released last night, giving researchers and investors a preview of clinical results for experimental drugs.
PROVOCATIVE: Chinese Deputy Ambassador to the UN Sun Lei accused Japan of sending military vessels to deliberately provoke tensions in the Taiwan Strait China denounced remarks by Japan and the EU about the South China Sea at a UN Security Council meeting on Monday, and accused Tokyo of provocative behavior in the Taiwan Strait and planning military expansion. Ayano Kunimitsu, a Japanese vice foreign minister, told the Council meeting on maritime security that Tokyo was seriously concerned about the situation in the East China and South China seas, and reiterated Japan’s opposition to any attempt to change the “status quo” by force, and obstruction of freedom of navigation and overflight. Stavros Lambrinidis, head of the EU delegation to the UN, also highlighted South China Sea
The final batch of 28 M1A2T Abrams tanks purchased from the US arrived at Taipei Port last night and were transported to the Armor Training Command in Hsinchu County’s Hukou Township (湖口), completing the military’s multi-year procurement of 108 of the tanks. Starting at 12:10am today, reporters observed more than a dozen civilian flatbed trailers departing from Taipei Port, each carrying an M1A2T tank covered with black waterproof tarps. Escorted by military vehicles, the convoy traveled via the West Coast Expressway to the Armor Training Command, with police implementing traffic control. The army operates about 1,000 tanks, including CM-11 Brave Tiger
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s largest contract chipmaker, said it expects its 2-nanometer (2nm) chip capacity to grow at a compound annual rate of 70 percent from this year to 2028. The projection comes as five fabs begin volume production of 2-nanometer chips this year — two in Hsinchu and three in Kaohsiung — TSMC senior vice president and deputy cochief operating officer Cliff Hou (侯永清) said at the company’s annual technology symposium in Silicon Valley, California, last week. Output in the first year of 2-nanometer production, which began in the fourth quarter of last year, is expected to
Taiwan’s drone exports surged past US$100 million in the first quarter, exceeding last year’s full-year total, with the Czech Republic emerging as the largest buyer, the Ministry of Economic Affairs said. Exports of complete drones reached US$115.85 million in the period, about 1.2 times the total recorded for all of last year, the ministry said in a report. Exports to the Czech Republic accounted for about US$100 million, far outpacing other markets. Poland, last year’s top destination, recorded about US$11.75 million in the first quarter. Taiwan’s drone exports have expanded rapidly in the past few years, with last year’s total
RSS